Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a member of a class of molecules called halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of li… Read more
Provectus Biopharmaceuticals Inc (PVCT) - Total Assets
Latest total assets as of September 2025: $419.90K USD
Based on the latest financial reports, Provectus Biopharmaceuticals Inc (PVCT) holds total assets worth $419.90K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Provectus Biopharmaceuticals Inc - Total Assets Trend (2002–2024)
This chart illustrates how Provectus Biopharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Provectus Biopharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Provectus Biopharmaceuticals Inc's total assets of $419.90K consist of 97.1% current assets and 2.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Provectus Biopharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Provectus Biopharmaceuticals Inc's current assets represent 97.1% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 30.6% of total assets in 2024, up from 3.4% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 94.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Provectus Biopharmaceuticals Inc Competitors by Total Assets
Key competitors of Provectus Biopharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Provectus Biopharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Provectus Biopharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Provectus Biopharmaceuticals Inc is currently not profitable relative to its asset base.
Provectus Biopharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.12 | 0.01 |
| Quick Ratio | 0.04 | 0.12 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.19 Million | $ -5.46 Million | $ -30.29 Million |
Provectus Biopharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Provectus Biopharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.44 |
| Latest Market Cap to Assets Ratio | 22.97 |
| Asset Growth Rate (YoY) | -30.5% |
| Total Assets | $1.01 Million |
| Market Capitalization | $23.12 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Provectus Biopharmaceuticals Inc's assets at a significant premium ( 22.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Provectus Biopharmaceuticals Inc's assets decreased by 30.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Provectus Biopharmaceuticals Inc (2002–2024)
The table below shows the annual total assets of Provectus Biopharmaceuticals Inc from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.01 Million | -30.55% |
| 2023-12-31 | $1.45 Million | -28.88% |
| 2022-12-31 | $2.04 Million | -42.01% |
| 2021-12-31 | $3.51 Million | +496.29% |
| 2020-12-31 | $589.20K | -60.11% |
| 2019-12-31 | $1.48 Million | -25.72% |
| 2018-12-31 | $1.99 Million | -42.14% |
| 2017-12-31 | $3.44 Million | -38.76% |
| 2016-12-31 | $5.61 Million | -72.55% |
| 2015-12-31 | $20.44 Million | -21.94% |
| 2014-12-31 | $26.18 Million | +30.87% |
| 2013-12-31 | $20.01 Million | +222.50% |
| 2012-12-31 | $6.20 Million | -53.53% |
| 2011-12-31 | $13.35 Million | -7.31% |
| 2010-12-31 | $14.40 Million | +40.74% |
| 2009-12-31 | $10.23 Million | -2.70% |
| 2008-12-31 | $10.52 Million | -33.05% |
| 2007-12-31 | $15.71 Million | -3.76% |
| 2006-12-31 | $16.32 Million | -5.74% |
| 2005-12-31 | $17.32 Million | +54.69% |
| 2004-12-31 | $11.20 Million | -43.53% |
| 2003-12-31 | $19.83 Million | -6.28% |
| 2002-12-31 | $21.16 Million | -- |